Brown Adipose Tissue Mimicking Head and Neck Cancer on PET Scan in a Patient on GLP‐1 Drug

Daron B. Harrison,Alisa L. Phillips,James B. Tansey,Travis J. Clarke,C.B. Wood,Lucien Nedzi,David L. Schwartz,Liza Makowski,D.N. Hayes,Grace Newman,John P. Gleysteen
DOI: https://doi.org/10.1002/lary.31815
IF: 2.97
2024-10-08
The Laryngoscope
Abstract:This case report highlights a 61‐year‐old female with class III obesity who presented with a neck mass. PET/CT imaging revealed extensive brown adipose tissue (BAT) uptake, mimicking metastatic disease, which was attributed to GLP‐1 receptor agonist therapy. This finding underscores the importance of recognizing medication‐induced imaging artifacts to avoid diagnostic errors in oncologic evaluations. To report a case of a patient undergoing GLP‐1 receptor agonist therapy in which increased FDG uptake in brown adipose tissue (BAT) mimicked metastatic head and neck cancer on PET/CT imaging. A 61‐year‐old female with Class III obesity presented with a right‐sided neck mass after significant weight loss following the use of the GLP‐1 receptor agonist, Semaglutide. PET/CT revealed FDG uptake in the right level II lymph node and extensive BAT uptake throughout the neck and mediastinum, complicating the diagnosis. Increased FDG uptake in the cervical and supraclavicular BAT regions led to diagnostic confusion, mimicking diffuse regional metastasis. Careful interpretation of PET/CT imaging, with fusion of anatomical and functional data, was essential to differentiate hypermetabolic BAT from malignant disease. Increased BAT FDG uptake, particularly in patients using GLP‐1 receptor agonists, can complicate the evaluation of head and neck cancer. Awareness of this interaction is critical to avoid misdiagnosis and overtreatment. Laryngoscope, 2024
medicine, research & experimental,otorhinolaryngology
What problem does this paper attempt to address?